Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021
Reata Pharmaceuticals (Nasdaq: RETA) will report its fourth quarter and full year 2020 financial results on March 1, 2021, before market open. A conference call is scheduled for the same day at 8:30 am ET, accessible by phone or via webcast. The earnings press release will be available on Reata's website shortly before the call and will remain accessible for one year. Reata develops innovative therapies targeting serious diseases by focusing on cellular metabolism and inflammation. Its lead candidates are bardoxolone methyl and omaveloxolone, which are investigational drugs.
- None.
- None.
PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on March 1, 2021.
Reata’s management will host a conference call on March 1, 2021 at 8:30 am ET. The conference call will be accessible by dialing (866)270-1533 (toll-free domestic) or (412)317-0797 (international) using the access code: 10152707. The webcast link is https://event.on24.com/wcc/r/3023787/38597EBB280C48468322B7487DECE1EF.
Fourth quarter and full year 2020 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
http://reatapharma.com
Investors:
ir@reatapharma.com
http://reatapharma.com/contact-us/
FAQ
When will Reata Pharmaceuticals report its financial results for 2020?
What time is Reata's conference call scheduled for March 1, 2021?
How can I access the conference call for Reata Pharmaceuticals?
Where can I find the earnings press release for Reata Pharmaceuticals?
What are the investigational drugs developed by Reata Pharmaceuticals?
